{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 26,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a before/after PET scan visual to demonstrate clinical efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/5",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.4,
        "x": 0.55,
        "y": 0.18
      },
      "kind": "image",
      "text": "TATCIST Subject #4 - Complete Response (by PSMA-PET scan)",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81039ef3-2d32-4280-9038-59e8688201ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.03,
        "y": 0.52
      },
      "kind": "list",
      "text": "Potential to change the mCRPC treatment paradigm. FPI-2265 monotherapy: first opportunity is in post-Pluvicto patients. PSMAfore data show opportunity for Pluvicto to move ahead of taxanes; FPI-2265 will follow upline. Potential to expand.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13d10627-c1b5-40f3-b8c2-5ada96ff1a4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "More than 300 patients treated with 225Ac-PSMA globally, including ~100 post-177Lu-PSMA. Achieved clinical POC in mCRPC. Safety results supportive of developability. Responses seen in patients naïve to and treated with 177Lu-PSMA.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b1eca9d-5292-4371-904c-380f40db3a1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-2265 is Currently the Most Advanced Actinium-Based PSMA Targeted Radiotherapy in Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a747e33e-4dea-4df7-b06f-3e022b322907",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 3,
      "beatId": "554bdf6e-c16b-49c5-afba-493e028c18d3",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents an overview of the radiopharmaceutical space and the potential of FPI-2265",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}